Synonym
Tubes
- Red or tiger top tube
- 5-7 mL of venous blood
Additional information
- Handle sample gently to prevent hemolysis
- Send sample to lab immediately
Info
- This test is ordered to evaluate for infectious mononucleosis (Epstein-Barr Virus infection)
- The monospot test is a rapid slide agglutination test to detect the presence of heterophile antibodies in the blood
- Heterophile antibodies are IgM immunoglobulins synthesized by B-cells during Epstein-Barr virus (EBV) infection and is the laboratory hallmark of infectious mononucleosis
- The basis of monospot test is the agglutination reaction of horse red blood cells on exposure to heterophile antibodies (qualitative), which can be titered (quantitative analysis)
Clinical
- The monospot test is indicated in the following conditions:
- As a screening test to detect infectious mononucleosis in persons presenting with symptoms of mononucleosis-like syndrome
- In pregnant women presenting with flu-like symptoms
- Evaluation of recent EBV infection
- To distinguish EBV infection from other causes of mononucleosis-like syndrome or glandular fever such as:
- Brucellosis
- Cat scratch disease
- Collagen-vascular diseases (especially lupus)
- Cytomegalovirus infections
- Drug reactions (phenytoin, sulfasalazine, dapsone)
- Hepatitis viruses
- HIV-1 seroconversion
- Listeriosis
- Lyme disease
- Rickettsial infections
- Subacute bacterial endocarditis
- Syphilis
- Toxoplasmosis
- Tularemia
- Primary infection by EBV in young children is often asymptomatic or mild. However, in adolescents and young adults it manifests as infectious mononucleosis, a self-limited clinical syndrome
- EBV is transmitted primarily by saliva through close mucocutaneous contact (hence also known as kissing disease) and has a very long incubation period (48 weeks)
- Infectious mononucleosis may be clinically characterized as:
- Fever (97% cases, persists for 7-10 days)
- Sore throat or exudative pharyngitis (>97%, disappears within 14 days after onset)
- Lymphadenopathy (>97% cases, most common affected is posterior cervical, axillary, and inguinal)
- Chills
- Malaise
- Fatigue
- Myalgias
- Splenomegaly (75%, regresses by 2128 days)
- Palatal petechiae (50%)
- Periorbital edema (33%)
- Hepatomegaly (20%, regresses by 2128 days)
- Maculopapular rash (10%)
- Heterophile antibodies:
- It appears about 1 week after the onset of the disease (detectable in 50% cases), peaks at 2-5 weeks (detectable in 60-90% cases), and declines to a low titer (
1:40) for 2-3 months after the onset of symptoms to 1 year (detectable in 75% cases), or up to 2 years (detectable in 20% cases) - Only 10-30% of children <2 years and 50-75% of children aged 2-4 years develop heterophile antibodies with primary EBV infection
- Heterophile antibodies are not directed against EBV and react with cells (hemagglutination) of other species such as horse RBCs, bovine RBCs, or sheep red cells
- These antibodies are not specific to infectious mononucleosis and are formed in serum sickness, drug reactions, and as naturally occurring antibodies to Forssman antigen
- A repeat monospot test in 7-14 days is recommended if the initial test results are negative in the presence of a strong clinical suspicion of EBV infection {Also consider EBV antibody testing [anti-VCA IgM, anti-VCA IgG, anti-EA (D), EBNA IgG]}
- The titer level does not typically correlate with the severity of the disease
Additional information
- The three classic criteria for laboratory confirmation of acute infectious mononucleosis due to EBV include:
- Lymphocytosis (>10-20%)
- Presence of at least 10% atypical lymphocytes (T-cells) on peripheral smear
- Positive serologic tests for EBV
- Related laboratory tests include:
- Antinuclear antibodies
- Cold agglutinins
- Complete blood count with peripheral blood smear evaluation
- Cryoglobulins
- Cytomegalovirus testing (CMV)
- EBV antibody testing
- Liver function tests
- Toxoplasmosis testing
Nl Result
- Normal result: Negative
- Method: Latex agglutination
High Result
A positive monospot test is associated with infectious mononucleosis (90-95%)
Conditions associated with false positive monospot test results include:
- Hepatitis A and B
- Leukemia
- Lymphoma
- Pancreatic cancer
- Rubella
- Systemic lupus erythematosus (SLE)
Low Result
Conditions associated with false negative monospot test results include:
- Children <2 years of age have up to 90% false positive rates
- Children 2-4 years of age have 25-50% false positive rates
- EBV associated with lymphoproliferative processes
- EBV in immunosuppressed persons
- Reactivated EBV infection
- Early testing (<1 week) into illness often results in false negative result (need to retest in 1-2 weeks)
- Not all patients develop heterophile antibodies (even at the peak at 2-5 weeks into the illness, up to 40% of patients still have a negative monospot test)
References
- ARUP's Laboratories®. Infectious Mononucleosis Slide Test by LA. [Homepage on the Internet]©2007. Last accessed on February 7, 2007. Available at URL: http://www.aruplab.com/guides/ug/tests/0050385.jsp
- Bell AT et al. Clinical inquiries. What test is the best for diagnosing infectious mononucleosis? J Fam Pract. 2006 Sep;55(9):799-802.
- eMedicine from WebMD®. Mononucleosis and Epstein-Barr Virus Infection. [Homepage on the Internet] ©1996-2007. Last updated on May 23, 2006. Last accessed on February 7, 2007. Available at URL: http://www.emedicine.com/PED/topic705.htm
- LabTestsOnline®. Monospot Test. [Homepage on the Internet]©2001-2007. Last reviewed on May 27, 2004. Last accessed on February 7, 2007. Available at URL: http://www.labtestsonline.org.uk/understanding/analytes/mono/sample.html
- Papesch M et al. Epstein-Barr virus infectious mononucleosis. Clin Otolaryngol Allied Sci. 2001 Feb;26(1):3-8.
- Ventura KC et al. Hematologic differences in heterophile-positive and heterophile-negative infectious mononucleosis. Am J Hematol. 2004 Aug;76(4):315-8.
- Vidrih JA et al.Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am J Med. 2001 Aug 15;111(3):192-4.